• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

    11/4/24 7:00:00 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XNCR alert in real time by email

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has initiated dosing of healthy volunteers in the first-in-human study of XmAb®942, an investigational high-potency extended half-life anti-TL1A antibody. Xencor continues to expect initial data from the ongoing study during the first half of 2025.

    "An anti-TL1A antibody engineered for improved target coverage with long duration of action could transform the clinician's therapeutic toolbox in inflammatory bowel disease," said Kenneth Hung, M.D., Ph.D., senior vice president, clinical development at Xencor. "We are excited to announce this first dosing of XmAb942 in healthy participants and believe that XmAb942's properties, including potentially class-leading potency, may result in a therapeutic option with improved clinical benefit and a more convenient dosing regimen than other anti-TL1A antibodies currently in clinical development."

    The Phase 1/2 randomized, double-blind, placebo-controlled study of XmAb942 will be conducted in three parts. In Phase 1, Part A will enroll healthy volunteers into single-ascending dose (SAD) cohorts, and additional healthy volunteers would receive repeat doses in Part B. In Phase 2, Part C will enroll patients with ulcerative colitis who would receive the dosing determined from Parts A and B. (ClinicalTrials.gov Identifier: NCT06619990)

    Xencor's poster with preclinical characterization of XmAb942 was presented at the United Europe Gastroenterology Week (UEGW) in October 2024. The poster is archived under the "Publications" and the "Events & Presentations" pages of the Company's website located at www.xencor.com.

    About XmAb®942

    XmAb®942 is a high-potency, extended half-life, investigational anti-TL1A antibody in development for patients with inflammatory bowel disease, such as ulcerative colitis (UC) and Crohn's disease (CD). The first generation of anti-TL1A antibodies, designed to block the interaction between the death receptor 3 (DR3) receptor and its ligand tumor necrosis factor (TNF)-like cytokine 1A (TL1A), have reduced disease activity in patients with UC and CD in multiple clinical studies. XmAb942's half-life is enabled by Xencor's validated Xtend™ Fc domain and could potentially support an eight- to twelve-week dosing interval in humans. Xencor initiated a Phase 1 dose-escalation study of XmAb942 in healthy volunteers in the fourth quarter of 2024.

    About Xencor

    Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

    Forward-Looking Statements

    Certain statements contained in this press release may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements that are not purely statements of historical fact, and can generally be identified by the use of words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "seek," "look forward," "believe," "committed," "investigational," and similar terms, or by express or implied discussions relating to Xencor's business, including, but not limited to, statements regarding expectations for clinical progress, planned receipt and presentations of clinical data, including the timing thereof, planned clinical trials, the quotations from Xencor's senior vice president, clinical development, and other statements that are not purely statements of historical fact. Such statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Xencor and are subject to significant known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks, including the ability of publicly disclosed preliminary clinical trial data to support continued clinical development and regulatory approval for specific treatments, and risks related to delays in receiving data from clinical trials, in each case as described in Xencor's public securities filings. For a discussion of these and other factors, please refer to Xencor's annual report on Form 10-K for the year ended December 31, 2023 as well as Xencor's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended to date. All forward-looking statements are qualified in their entirety by this cautionary statement and Xencor undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241104306659/en/

    Get the next $XNCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XNCR

    DatePrice TargetRatingAnalyst
    4/21/2025Outperform
    William Blair
    12/12/2024$37.00Overweight
    Wells Fargo
    12/2/2024$20.00 → $30.00Neutral → Overweight
    Piper Sandler
    4/16/2024$56.00 → $38.00Buy
    BTIG Research
    2/28/2024$37.00 → $24.00Overweight → Neutral
    Piper Sandler
    5/19/2023$42.00Buy
    BofA Securities
    12/6/2022Outperform
    Cowen
    10/13/2022$58.00Outperform → Strong Buy
    Raymond James
    More analyst ratings

    $XNCR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Xencor Inc.

      10-Q - Xencor Inc (0001326732) (Filer)

      5/7/25 4:09:38 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

      8-K - Xencor Inc (0001326732) (Filer)

      5/7/25 4:03:09 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Xencor Inc.

      DEFA14A - Xencor Inc (0001326732) (Filer)

      4/23/25 4:06:50 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Xencor Reports First Quarter 2025 Financial Results

      -- Recent interim Phase 1 study results for XmAb942 (Xtend™ anti-TL1A) support a 12-week maintenance dosing interval in XENITH-UC, a Phase 2b study in participants with ulcerative colitis, to begin in the second half of 2025 -- -- Chief development officer and former independent director, Nancy Valente, M.D., to transition to senior advisory role -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2025 and provided a review of recent business and program updates. "Recently presented interim Phase 1 results suppo

      5/7/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

      -- XENITH-UC, a Phase 2b study of XmAb942 in participants with ulcerative colitis, to begin in the second half of 2025 -- -- Single and multiple doses of XmAb942 are well tolerated and safety profile is consistent with the anti-TL1A drug class -- -- XmAb942 half-life supports a 12-week maintenance dosing interval in XENITH-UC -- -- Lead selection for XmAb TL1A x IL23p19 program on track for first-in-human study start in 2026 -- -- Management hosting webcast and conference call at 5:00 p.m. ET / 2:00 p.m. PT today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced

      4/29/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Appoints Todd Simpson to Board of Directors

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies and in public accounting. Most recently he served as CFO at Seagen Inc. through its acquisition in 2023. "Mr. Simpson is an accomplished finance and operations executive with broad experience in corporate strategy, and he played a key role in transforming a small development-stage biotech company into one of the most successful growth c

      3/13/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Xencor Appoints Todd Simpson to Board of Directors

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies and in public accounting. Most recently he served as CFO at Seagen Inc. through its acquisition in 2023. "Mr. Simpson is an accomplished finance and operations executive with broad experience in corporate strategy, and he played a key role in transforming a small development-stage biotech company into one of the most successful growth c

      3/13/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Appoints Bart Cornelissen as Chief Financial Officer

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance at Seagen Inc., where he was instrumental in the company's transformation into a global, multi-product organization that generated over $2 billion in annual revenue. "Bart's exceptional track record in financial planning and analysis

      4/9/24 8:01:00 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Barbara J. Klencke, M.D., to its board of directors. Dr. Klencke has more than 20 years of biopharmaceutical product development experience, and she most recently served as chief medical officer and chief development officer at Sierra Oncology through mid-2023. While at Sierra Oncology, she built a highly effective clinical development organization and led its strategy and execution, culminating in the approval of Ojjaara™ for myelofibrosis following the company's acquisition by GSK. "D

      9/19/23 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Development Officer Valente Nancy sold $50,914 worth of shares (4,616 units at $11.03), decreasing direct ownership by 9% to 49,169 units (SEC Form 4)

      4 - Xencor Inc (0001326732) (Issuer)

      5/6/25 4:40:24 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SR. VICE PRESIDENT & CFO Cornelissen Bart Jan sold $30,233 worth of shares (3,750 units at $8.06), decreasing direct ownership by 6% to 61,348 units (SEC Form 4)

      4 - Xencor Inc (0001326732) (Issuer)

      4/14/25 4:13:39 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Simpson Todd E

      4 - Xencor Inc (0001326732) (Issuer)

      3/13/25 7:03:03 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Xencor Inc.

      SC 13G/A - Xencor Inc (0001326732) (Subject)

      11/14/24 6:16:13 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Xencor Inc.

      SC 13G/A - Xencor Inc (0001326732) (Subject)

      11/14/24 1:22:36 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Xencor Inc.

      SC 13G/A - Xencor Inc (0001326732) (Subject)

      11/12/24 4:01:23 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Financials

    Live finance-specific insights

    See more
    • Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

      -- XENITH-UC, a Phase 2b study of XmAb942 in participants with ulcerative colitis, to begin in the second half of 2025 -- -- Single and multiple doses of XmAb942 are well tolerated and safety profile is consistent with the anti-TL1A drug class -- -- XmAb942 half-life supports a 12-week maintenance dosing interval in XENITH-UC -- -- Lead selection for XmAb TL1A x IL23p19 program on track for first-in-human study start in 2026 -- -- Management hosting webcast and conference call at 5:00 p.m. ET / 2:00 p.m. PT today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced

      4/29/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

      – Phase 1 healthy volunteer study of half-life extended anti-TL1A antibody XmAb942 to dose first subject in Q4 2024, with data anticipated in the first half of 2025 – – XmAb® T-cell engagers plamotamab (CD20 x CD3) and XmAb657 (CD19 x CD3) to be evaluated in autoimmune diseases, with respective Phase 1b/2a and Phase 1 studies to initiate in 2025 – – Ongoing Phase 1 dose escalation of XmAb819 (ENPP3 x CD3) in advanced clear cell renal cell carcinoma shows initial encouraging clinical activity including RECIST responses – – Management hosting webcast and conference call at 8:00 a.m. ET / 5:00 a.m. PT today – Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing

      9/9/24 7:31:00 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that management will host a webcast and conference call at 8:00 a.m. ET (5:00 a.m. PT) on Monday, September 9, 2024 to introduce new XmAb® programs in development for the treatment of patients with autoimmune diseases and to provide updates on continued progress in dose escalation with first-in-class oncology programs, including XmAb819 (ENPP3 x CD3) in patients with advanced clear cell renal cell carcinoma and XmAb808 (B7-H3 x CD28) in patients with advanced solid tumors. The live webcast may be accessed through "E

      9/6/24 8:01:00 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Xencor

      William Blair initiated coverage of Xencor with a rating of Outperform

      4/21/25 8:40:03 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Xencor with a new price target

      Wells Fargo initiated coverage of Xencor with a rating of Overweight and set a new price target of $37.00

      12/12/24 8:18:37 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Xencor from Neutral to Overweight and set a new price target of $30.00 from $20.00 previously

      12/2/24 10:12:11 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gorman Kevin Charles bought $1,013 worth of shares (53 units at $19.12), increasing direct ownership by 1% to 5,060 units (SEC Form 4)

      4 - Xencor Inc (0001326732) (Issuer)

      2/15/24 4:02:46 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care